Published in PLoS One on April 11, 2014
Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2. Cancer Gene Ther (2015) 0.87
Preventing High Fat Diet-induced Obesity and Improving Insulin Sensitivity through Neuregulin 4 Gene Transfer. Sci Rep (2016) 0.81
MicroRNA let-7b suppresses human gastric cancer malignancy by targeting ING1. Cancer Gene Ther (2015) 0.81
Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther (2014) 0.79
MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1. Int J Clin Exp Pathol (2015) 0.79
The up-regulation of miR-300 in gastric cancer and its effects on cells malignancy. Int J Clin Exp Med (2015) 0.77
Nucleostemin regulates proliferation and migration of gastric cancer and correlates with its malignancy. Int J Clin Exp Med (2015) 0.76
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol (2016) 0.75
Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers. Mol Pharm (2014) 0.75
HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PLoS One (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res (2004) 25.98
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol (2011) 2.36
Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem (2000) 2.11
A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem (1997) 1.99
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res (2006) 1.94
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res (1999) 1.60
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.57
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene (1999) 1.46
Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal (2006) 1.40
High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res (2008) 1.38
Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg (2009) 1.34
Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev (2012) 1.27
Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer (2002) 1.20
Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol (1993) 1.19
Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem (2003) 1.17
Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet (2011) 1.17
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol (2005) 1.12
Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer (2004) 1.07
High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One (2011) 1.06
Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci (2012) 1.00
Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene (2000) 0.97
Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res (2009) 0.96
Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets (2012) 0.94
Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig (2001) 0.92
Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis. Diagn Mol Pathol (2007) 0.89
Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol (2010) 0.89
Overview of methodological quality of systematic reviews about gastric cancer risk and protective factors. Asian Pac J Cancer Prev (2012) 0.80
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol (2010) 0.80
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Invest New Drugs (2012) 0.79